We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DPRO:NASDAQDraganfly Inc. Analysis

Data as of 2026-03-29 - not real-time

$4.59

Latest Price

8/10Risk

Risk Level: High

Executive Summary

DPRO is trading at $4.59, barely above its technical support of $4.50 and well below its 20‑day ($6.27), 50‑day ($7.25) and 200‑day ($6.67) simple moving averages, signaling a prolonged downtrend. The RSI of 31 suggests the stock is oversold, while the MACD histogram remains negative, indicating lingering bearish momentum. Volatility is extreme at over 119% 30‑day and beta exceeds 1.6, pointing to a highly responsive price action. However, the price‑to‑book ratio of 1.94 and price‑to‑sales of 21.5, combined with a cash pile of $94 M against modest debt, imply the market may be undervaluing the balance sheet.
Fundamentally, revenue grew 18.5% YoY, but operating and net margins remain negative, and cash flow is still a drain. Recent analyst sentiment turned positive, with a Zacks Rank 2 “Buy” upgrade and a “Greed” reading on the fear‑greed index, while upside potential exceeds 200% versus the current price. The company’s cash runway and low debt give it flexibility to invest in its drone and telehealth platforms, yet profitability and regulatory clearance remain key hurdles for long‑term investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI indicating oversold conditions
  • Price hovering just above key support
  • Recent Zacks Buy upgrade boosting short‑term sentiment

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong cash position with minimal debt
  • Revenue growth of 18.5% and expanding drone market
  • Upside potential >200% based on target price estimates

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Persistent negative operating margins and cash flow
  • Regulatory uncertainties surrounding UAV deployments
  • Need for sustainable profitability to justify valuation

Key Metrics & Analysis

Financial Health

Revenue Growth18.50%
Profit Margin-297.25%
ROE-45.41%
ROA-23.33%
Debt/Equity0.28
P/B Ratio1.9
Op. Cash Flow$-23875720
Free Cash Flow$-15912597
Industry P/E32.0

Technical Analysis

TrendNeutral
RSI31.3
Support$4.50
Resistance$7.70
MA 20$6.27
MA 50$7.25
MA 200$6.67
MACDBearish
VolumeStable
Fear & Greed Index65.98

Valuation

Target Price$13.86
Upside/Downside201.98%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.66
Volatility119.34%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.